Patrick Cox’s “Build Transformational Wealth from Three Tiny Companies”

"Revealed: The 3 Hidden Companies About to Change Every Life on Earth" -- looking at the launch campaign for Transformational Technology Alert

By Travis Johnson, Stock Gumshoe, October 17, 2013

Irregulars Quick Take Paid members get a quick summary of the stocks teased and our thoughts here. Join as a Stock Gumshoe Irregular today (already a member? Log in)

Patrick Cox has found a new home — he has issued many a tempting teaser campaign over the years, and I was wondering what had happened to him after leaving his Breakthrough Technology Alert in the hands of Ray Blanco this Summer.

Well, I can stop wondering — he jumped to a new publisher and just launched a new letter called Transformational Technology Alert for John Mauldin at Mauldin Economics. And it looks like he’s going to be continuing to spoon up the life-changing technologies — and, of course, promises of unheard-of wealth from early investments in the companies in the forefront of these technologies.

Like his old letter, this one’s pricey — “list price” $1,995 and “on sale” launch price of $895, which is similar to the pricing that was pitched for his previous publication in recent years. That indicates he’s still looking at very small stocks (if you recommend a lot of stocks with sub-$100 million market capitalization, it’s a lot better to have 100 readers paying $1,000 a year than to have 2,000 people paying $50 a year — you have a better chance of not causing the share price to go crazy when your readers buy or sell it).

So yes, before we even start to unravel his favorite picks that he’s using to launch his new letter, we should mention that they’re probably very small stocks, and we’re not going to be doing them any favors by sharing them with all our favoritest friends (that’s you). I have no idea whether or not you’ll like the stocks we’re going to find today, but please don’t rush out and buy ’em just because I’m sharing the tickers with you — if they go up because of Patrick’s attention and for no other real fundamental reason in the days ahead, odds are they’ll come back down again when the attention wanes. They almost always do.

So what’s Patrick teasing now?

Well, let’s start with a taste of the teaser pitch …

“When you finish this letter, please speak to your children and grandchildren.

“What you’ll see below will affect their lives just as deeply as yours.

“That’s because you’re about to see a little-known story with the power to make you wealthier than you ever imagined.

“It also stands to change your life and the lives of everyone in your family in astonishing ways beyond the collection of wealth….

“What you’re about to see could release you from worries about struggles in retirement, providing for your family, or making certain your children and grandchildren have every advantage starting out in life.

“The opportunity I’ll reveal to you represents what I believe is the greatest wealth-creation event of this century.”

So have no fear, Patrick Cox did not leave his hyperbole machine at Agora — he’s still got it, and it’s chugging away. His past ads touted the emerging medical technologies as being similar to the introduction of the printing press, or of the railroad, or computers, real advances that dramatically changed the globe, and he’s essentially on the same track today with the stocks he’s touting.

More from Cox:

“The three companies I will reveal to you here, taken together, could change every life on earth… for the better.

“You don’t need special connections or ‘venture capital’-style wealth to participate.

“That’s what makes what I’ll reveal to you so special.

“You can take a stake in all three of these revolutionary firms for a pittance….

“One share of each of the three companies in Build Transformational Wealth from Three Tiny Companies currently totals just $15.84.”

He talks about the founding of Pfizer, which was started with $2,500 in borrowed money and became a $200 billion company, and the similar story of the launch of Merck (he does not, of course, mention the hundreds of companies that hoped to become the next Pfizer and have languished for decades or gone bankrupt, that would take some of the fun out of it).

But OK, we get the idea, right? Small stocks, huge potential. Now … what are the actual companies?

Well, we start with the one that seems to be his favorite, here’s how he touts it:

I Believe This Company Will Go Down in History as the Most Important (And Lucrative) Firm Ever Created

He’s not messing around there, eh?

“Imagine if one company had the lead in the quest to rebuild strong, healthy hearts, livers, lungs… and also cartilage… tendons… and more.

“Now imagine if this company also had a way to test for cancer that was accurate years in advance… notifying folks long before the cancer threatened a person’s life.

“Now… also imagine if this company had patented processes that made it the unofficial clearinghouse for any other company on earth that wanted to do similar work.

“All three of these traits exist in one company.”

So … of course you want to buy that stock, right? So who is it? More clues:

“This company recently hired the ex-head of the Food and Drug Administration (FDA) to serve on its board.

“This company has subsidiaries in China… relationships with geniuses in Europe and Israel… but is based in and trades on an exchange right here in the US.

“And when I recently spoke with the CEO, he revealed ongoing work that floored me.

“In short, his company has devised a flexible, painless, and natural ‘framework’ that can be placed inside an organ or, for example, a knee.

“This natural, biological framework then regrows into whatever organ or joint… or cartilage… or artery… is needed…..

“… in late August, the company announced it has received approval to begin human clinical trials on one of its regenerative framework products in a European country.

“Earlier in August, the company announced it had found what it thinks could be the specific gene that raises the likelihood of breast cancer. The finding was released in the scientific journal Biomarkers in Medicine.

“When word gets out about what this company is doing… I doubt many people will know how to react.

“Plus, as I mentioned, this company currently has patents and agreements on how these complex processes function.

“What I mean is, this company owns the world’s premier library of information on how to test these treatments.”

And Cox is expecting a catalyst, too, which is the urgency he throws in to try to get you to act quickly on your subscription — he thinks news will be coming in eleven days:

“I’m expecting further news about this company on October 28. I don’t want you to miss it… I want you to be on board long before then.

“The news I’m expecting on October 28 deals with this company announcing to the world just how powerful its platform really is.”

So what’s the company?

Well, we fire up the good ‘ol Thinkolator and get our answer pretty quickly this time — Patrick Cox is again teasing his old favorite BioTime (BTX)

Cox has been all over this stock for almost as long as Stock Gumshoe has existed (we launched in 2007, in case you’re counting) — I think the first time I wrote about a Patrick Cox teaser for BioTime was back in the Fall of 2008 and he was expecting a dramatic announcement then, too. The stock has been wildly volatile over the years, getting as high as $10 or so in 2010 after they got relisted on the AMEX (they traded over the counter before that), and his touting of the stock over the years has been quite consistent — he’s said pretty much the same things whether the stock was trading at less than $2 or at $7.50 — the stock is at $3.75 now and has mostly bounced up and down in the $4 neighborhood over the last two years.

BioTime is run by Michael West, who also founded Geron (GERN) and is a stem cell pioneer, so that’s really the focus of the company — indeed, they just recently bought access to the Geron stem cell portfolio, drugs and patents, so they continue to try to grow into the core provider of stem cell materials and data as well as a developer (through a bunch of subsidiaries) of stem cell-related treatments, everything from aesthetics to cancer drugs.

And to be honest, I haven’t looked very closely at the company in recent years and I have a hard time understanding them. They’ve grown quite a bit in market cap over the last five years, both because the stock has risen since 2008 and because they’ve more than doubled their share count since then, but as far as I can tell they are still a very long-term speculation from any kind of valuation perspective — they still have to sell more stock to keep going most quarters, and they burn through about $25 million a year in cash, mostly for R&D. They do have revenue that has gradually risen over the years, but it’s still at a trivial level — revenue has never come close to covering even half of their operating expenses, and that relationship between inflow and outflow has been worse, not better, with the last twelve months bringing in about $4 million in revenue (gross revenue, total sales — not profits) and sending about $30 million out the door in expenses.

So you really have to believe in the story for BioTime, and think that they’re building something transformation, to think that they’re worthy stewards of your investment dollars. If you’re more interested in that short term stuff Cox teased about, you’ll have to guess about what they mean — they are likely to release their next quarterly update in early November, and I suppose they could always release R&D news or deal details, but beyond that they don’t have any presentations on their calendar for the balance of the month. The big news that has shaken up their balance sheet lately is the acquisition of those Geron patents and programs (though Geron shareholders liked that a lot more than BTX shareholders did), so they may well put together some kind of presentation about that potential … dunno.

Now, I mentioned at the top that these kinds of little stocks are not for the faint of heart — they go up and down wildly. Here’s another quick excerpt from Cox’s ad, lest you think that he’s only promising that these will make you rich tomorrow (that’s the implication, of course, but not the direct promise):

“Yes, the companies I’ll show you are best viewed as tiny speculations. Don’t buy them with dollars you need month to month. The best way to play these companies is in small, reasonable bites. That way, your transformational benefits build over time….

“This means $1,500 or $2,500 could be enough to take a stake that sustains your family with vast wealth for generations to come.

“(Remember, full disclosure commands that I advise you again – use ‘speculation capital’ to buy these stocks. NOT money you need to pay the mortgage or your electric bill.)”

So does BioTime sound like it’s about to begin another upswing? See some potential there? You’ll have to spend more time looking at their plans and their subsidiaries than I did to make any kind of educated guess, but we can at least point you to the name and ticker and send you on your way … and if you’d like to come back and report what you think with a comment below, well, we’ll be delighted to hear your thoughts.

And yes, there are two other picks teased in this new ad — I’m running out of time, but we’ll get to those other two as soon as we can in a future article, early guesses to get your brain percolating are that he’s still pounding the table for Nanoviricides (NNVC) and maybe also Inovio (INO), but I haven’t fed those through the Thinkolator yet or made certain they’re matches for the current teaser. If you feel like pitching in on those and saving your friendly neighborhood Gumshoe the effort, well, you’re welcome to it!

Related Gumshoe Articles

“How a Company You’ve Never Heard of Could End Alzheimer’s Disease and Save America’s Financial Future”

A Quick Friday File look at a Patrick Cox teaser

7 Comments Read More

Leave a Reply

47 Comments on "Patrick Cox’s “Build Transformational Wealth from Three Tiny Companies”"

avatar

Dick
Guest
0
Dick
October 17, 2013 3:56 pm

There is the new 10 best stocks for 2014 from Street Authority that supposedly beat the market by a factor of 3 since 2008. Should we start a challenge?
As to BioTime, I don’t have it to watch this kind of stocks. Wish them better success than Yield “The Toothless” Shark.

Jeff
Guest
0
Jeff
October 17, 2013 4:41 pm

I used to subscribe to Breakthrough Technology and yes, Nanoviricide was the stock being pitched…I suspect it’s the same now.

Jimmy
Guest
0
Jimmy
October 17, 2013 5:38 pm
I have been reading John Mauldin for quite a number of months and I find his writings very fascinating. So, with the invite to join in a live chat with his new partner, Patrick Cox, I made a special effort to be available for the chat. While I heard some interesting thoughts on future medical breakthroughs, I was less impressed than I expected. Now, I realize it was all a ploy to get high priced subscriptions to a new newsletter-many of which are worth a dime a dozen. Maybe this will be different, I do not plan to subscribe. It… Read more »
Thomas deLackner
Guest
0
Thomas deLackner
October 17, 2013 6:56 pm
John Mauldin can be a brilliant analyst of financial matters, but his trust in his friends can be a bit naive. (Being brilliant, he is easily taken in by brilliant language.) BTX is a long-shot going up against some very well-funded established companies, none of which may get to their goal within the next five or ten years. Mauldin promoted Cox’s promotion of STSI, so I looked up the patent portfolio backing anatabine citrate. Apart from vague claims about a remedy for depression, all they have is patents for the production of anatabine citrate. And, of course, no useful research… Read more »
Heathcliff Slocumb
Guest
0
Heathcliff Slocumb
October 23, 2013 3:32 am

It’s okay, Patrick Cox doesn’t know anything about NNVC either. Well, he knows what the company puts out in press releases and regurgitates it with a lot of extra hype. If you want to pay $2,000 for that, let me know. I’ll only charge you $1,000.

Andy
Guest
0
Andy
October 23, 2013 10:59 am

it was SSTI (not STSI) he recommended: they are a stem cell company that also makes skin cream based on the stem cell growth factors.

Robert G.
Guest
0
Robert G.
October 24, 2013 12:07 pm
I can definitely remember a couple of years ago when John went crazy about ISCO even adding that he was using their stem cell cream himself and it was taking, like, 10 years of age off his face (plus was offering a “deal” on the product itself to his readers at something like over $200 for a tiny jar). It was around $1.75. I remember it going to a little over $2 after his tout before a continual slide. I finally took it off the radar at around 35 cents. I just saw it’s about 16 cents now. Let’s just… Read more »
agau
Member
2
agau
October 27, 2013 12:23 pm

My recollection is akin to yours – about the stem cell face cream, the stock price, and his macro touts.
And credit where credit is due too. I still hold ARII with a nice 25% gain.

agau
Member
2
agau
October 27, 2013 12:15 pm

I don’t like John’s new ‘friends’.
IMO, a growing number of friends of questionable repute.

agau
Member
2
agau
October 27, 2013 12:13 pm

Ditto your initial comments, only changing ‘months’ to ‘years’.
But really valuable macro information is often free. IMO, that’s what John is best at.
Valuable micro is a whole other story…

Stuart
Guest
0
Stuart
October 17, 2013 6:13 pm
I have attended conventions where both Cox and West spoke for the past 4 years. Very informative – very interesting and yes, they will make you certain that the recipe for immortality is literally just around the corner and they hoild all the cards. I certainly hope they’re right, but as an investor I have problems. The most glaring is that the Founder of the company has to keep coming back year after year to investor conferences to raise money. There are a LOT of deep pocket intelligent investors (say, for instance hedge fund managers) who could literally buy Biotime.… Read more »
Dr. KSS MD PhD
Guest
0
karma swim swami
October 17, 2013 6:54 pm
Travis: Thanks for an excellent synopsis. The problem with BTX is that it seems always to have been touted by one teaser-writer or another. In the 90’s, it was pushed by Jonathan Steinberg’s Individual Investor magazine before it went belly up, and then was later pushed by Steinberg’s Wisdon Tree outfit in its former “Special Situations” letter. The reason it was pushed way back then was because of hopeless promises and speculation surrounding Hextend, BTX’s plasma extender. Hextend NEVER lived up to ANY of its hype, and is largely not in use. It was the Hextend hoopla, along with market… Read more »
thomas smith
Guest
0
thomas smith
October 17, 2013 9:36 pm

Please re-design your e/m notice and put the unsubscribe at the bottom. The current location can result in receivers accidentally unsubscribing.

safari_phil
Guest
0
October 17, 2013 9:45 pm

Thank you for the insight. I was searching other sources to find out why Geron was rising recently, but I was unaware of the connection to Biotime. Sold it while I was ahead before any bad news could knock it down. You’re the best ‘Gumshoe.’

T.L.
Guest
0
T.L.
October 17, 2013 10:27 pm

I wish these writers would push a good company and not these junky ones. I am curious as to what the newsletters are saying about twitters upcoming offering. Does anyone have a idea?

Joseph E Fasciani
Guest
0
October 18, 2013 1:08 am

I bought a year’s trial sub and can honestly say it was one of the two VERY worst performing analyst-newsletters I’ve ever read or know of. If you can find a scummier one, let us know. As I told their subscription department at the time I cancelled, “IF I had seen his dismal track record BEFORE, I’d never have bought into it.” But that’s the point of scams, isn’t it?

Joseph E Fasciani
Guest
0
October 18, 2013 1:12 am

The other one is a Christian religious nut [and I’m a Christian Quaker!], Jeb Handwringer should be his name, as you sweat over yr plunging shares! He’s a shill for several companies, not all, maybe only 98%, and he ALWAYS has a glimmer of hope for you on the way down. Well I’m sure a stalk of straw looked like gold to someone who survived the sinking of the Titanic, but that didn’t get them through the long, cold night….

Gary
Guest
0
Gary
October 18, 2013 3:32 am
Well done Travis. I had just received the hype from JMauldin and, yes, Patrick Cox has lost none of his BS machine. It’s a shame Mauldin doesn’t see Cox as the hypemeister that he is. Mauldin is a good analyst on the economy and an enjoyable writer but… As for Biotime, whew, you would have to have been in and out in perfect timing to make any money. There are others he continues to push. Like a stopped clock he may be right sometime, but do you want to take the risks involved, not me. I once bought into it… Read more »
Richiv
Guest
0
Richiv
October 18, 2013 4:21 am
On Mauldin: when I began to read his newsletter six or seven years ago, it was a good encapsulation of his macro views, which were normally different from those of your average sell-side market strategist. The only overtly commercial aspect was linking to Amazon in order to help his book sales. Gradually however, he has built out his platform to offer a much wider range of products, e.g. Yield Shark, Bull’s Eye Investor, etc. and now Transformational Technology Alert. These newsletters tout input from “his personal research team”, or “inner circle of the biggest and best money managers in the… Read more »
guyd
Member
0
guyd
October 18, 2013 7:58 am

Agreed, I have read the Mauldin email newsletters over the past 3 years or so. He has been bearish while the stock market has been surging. However he has been bullish on biotech, and I agree with him on that. Also, he never gives specific stock picks, but wants to pawn you off to his friends for advice (for a fee of course)

PattyDinero
Guest
0
PattyDinero
October 22, 2013 12:02 pm

Agreed 110% that Maudlin was great to read 7-10 yrs ago. Now it’s noise and junk “mail”. Truly disappointing. Once I used to read carefully his commentary, now it’s filled w commercial interruptions that are borderline snake oil salesman-like. He is quickly losing credibility.

Howard McCalla
Guest
0
October 18, 2013 12:47 pm
Dear Gumshoe, Great analysis. I did not expect you to pick up on this story this quickly. I have been reading John Mauldin for a number of years and have been impressed with his writing and analysis. He has called a number of trends in the last ten years or so. I have used his opinions to offset a lot of “hype” from other sources. I actually read his email long before I found Stock Gumshoe. I have been concerned the last two years or so about a strong trend to “guest writers” and “friends”. I had decided that he… Read more »
Greg Stern
Guest
0
Greg Stern
October 18, 2013 1:59 pm
I also am a long-time Mauldin reader, and tend to be generally impressed with his thinking. He’s been touting Patrick Cox as a partner for years. Mauldin- who I gather to be a pretty intelligent person- made the argument about three years ago that he was so convinced that biotech was going to be the next big asset bubble, that he had started investing in individual stocks for the first time in decades. The pitch with this most recent letter is almost identical to a pitch made about 3 years ago- buy Patrick’s newsletter for $895 a year. He hooked… Read more »
PattyDinero
Guest
0
PattyDinero
October 22, 2013 12:07 pm

Great job Greg!

Fred
Guest
0
Fred
October 23, 2013 1:15 pm

NNVX is a Pump & Dump; it’s listed on the Pumps&Dumps site: http://www.pumpsanddumps.com/p/hall-of-fame-m-z.html
I never buy anything without first checking the P&D site. They’ve saved me from several expensive mistakes. And I wouldn’t trust Patrick Cox as far as I could throw a Water Buffalo.

Earl
Guest
0
Earl
October 24, 2013 10:56 am

Uh, does the FDA usually give fast track status to a “P&D” company?

Jason C.
Guest
0
Jason C.
October 18, 2013 3:57 pm
I also follow John Mauldin’s emails and thoughts and find him very knowledgable but regarding economics but not so hot on specific stock advice. I was researching the third pick by the Cox character and found it. it is Galectin Therapuetics (GALT) and I saw that John Mauldin is a director in the insider trading section on yahoo finance. He has been in and has been buying stocks since the $2 and change timeframe. The numbers on the company are horrible, as expected and thanks to you for giving me the final piece of the pie on this one regarding… Read more »
Jay Koch
Guest
0
Jay Koch
October 18, 2013 8:03 pm
Thanks again, Travis. I find your summaries a real time-saver, and very entertaining to boot. I have been a regular reader of both Mauldin and the Agora publications for quite awhile. Mauldin is informative and well-reasoned, and both he and his guests often include excellent graphics and statistics to support their arguments. I find Patrick Cox and his ilk (often including the agora team) a different story. You have to be impressed by their narratives and the calls to urgent action they include. Their track record is unimpressive. My question is this: are they hired by the firms whose stock… Read more »
Phoenix 7
Guest
0
Phoenix 7
October 20, 2013 12:38 pm

Looking at the aforementioned stocks , and putting them through a sophisticated computer program GALT is perhaps best of the lot! If you are looking for a perhaps a better pick , which is not pumped , as far as I can ascertain DDXS should do better over the short term than any mentioned in this response by Travis! Good Luck To All !

MLTanner
Irregular
1
MLTanner
October 20, 2013 3:45 pm

Travis,
I think you’ve nailed BioTime and Nanoviricides, but I would agree with Jason C that the third company is Galectin.
Check out:
http://www.news-medical.net/news/20130410/Galectin-Therapeutics-provides-details-on-first-in-man-Phase-1-clinical-trial-of-GR-MD-02.aspx
or
http://www.pharmabiz.com/NewsDetails.aspx?aid=77149&sid=2

will
Guest
0
will
October 21, 2013 11:41 am

John Mauldin seems to have decided to cash in on his well-deserved reputation as a macroeconomics analyst with “services” that may be of lesser quality than his weekly email.

Sue
Guest
0
October 21, 2013 12:14 pm

Travis, If you’re interested in Patrick Cox, he had an very recent article in a Port Phillip Publishing letter in Australia : The Daily Reckoning but it was attributed to the US publication of same name. Also , if you want to see hyperbole have a look at Daily Reckoning (aust) for the Revolutionary Tech letter…..unfortunately it’s about $1100-1200 yearly!!!! Enjoy, Sue. Please excuse atrocious layout….whenever try fix, it just gets worse. Sue.

Fred
Guest
0
Fred
October 21, 2013 6:30 pm

I heard a joke some time ago; it went,

What’s the fastest way to become a millionaire? You take a Billion dollars and invest in an airline.
But I know of a quicker road to penury: Take all your money, and invest it according to Patrick Cox’s advice.

No need to thank me; just think of it as a public service.

Fred
Guest
0
Fred
October 22, 2013 5:11 pm
Yes, Bob, that IS too bad. These guys all use pretty much the same modus operandi: spin a good story, to generate investor interest. The suckers–that’s us–buy in, creating a nice rally, and that’s when they spring the trap: the insiders–including this Cox jerk, I’d wager–dump their millions of shares into that rally, and we’re left holding the empty bag. I wouldn’t mind running into this Patrick Cox, on the street. I’ve got a size 12, with his name on it. We do have an ally–a couple allies, actually–however, Travis, Ol’ Doc Gumshoe, and a website called Pumps&Dumps: http://www.pumpsanddumps.com/ Travis… Read more »
Bob
Guest
0
Bob
October 22, 2013 12:48 am

Too bad I had to read your advice Fred ,after buying Cox’s Breakthrough Technology Alert for $895…… then losing big on 3 of his 4 recommendations. Maybe he should be a science teacher instead of an investment adviser…either way….he’s certainly a convincing writer……live and learn….

Fred
Guest
0
Fred
October 22, 2013 5:20 pm

I don’t know, Bob…Science Teacher? I don’t think he knows science very well. I think Mr. Cox’s true calling lies in the field of professional BS artist. I happen to have great respect for good teachers and professors, and a real disdain for charlatans, such as Patrick Cox. And yes he can write, too bad he uses his writing skill to bamboozle people, to victimize and cheat them. No, I think his true calling is that of Jailbird.

Don t. No
Guest
0
Don t. No
October 22, 2013 3:26 pm
I’m a retired money manager. Regarding newsletter publishers; invest in any of their recommendations at great risk to your wealth. These so-called gurus and their copy writers and publishers hype a multitude of stocks and strategies to separate the many fools from their money. Remember if you aren’t an insider you are an outsider. If you believe you will get rich buying a newsletter which costs $39 to $1995, then I have a priceless piece of art to sell you that hangs on my refrigerator courtesy of my youngest son. Now regarding, John Mauldin, I’ve known him personally for 20… Read more »
Ramon
Guest
0
Ramon
October 22, 2013 9:11 pm

I believe the accompanying chart comes in handy when it comes to the discussion of this sort of investment opportunities:
http://www.businessinsider.com/biotech-stock-blow-ups-since-1990-2013-10

april39
Irregular
7
October 24, 2013 1:44 pm

In reference to John Mauldin above: To be blunt if not polite I’ll use an expression that a North Carolina fellow used in 1964 on the division v.p. of a huge “defense contractor who was more interested in shipping a bad Polaris missile guidance package on time than a good package late. ” I can hot make chicken salad out of chicken s—.”

Junior
Guest
0
Junior
October 27, 2013 12:19 pm

I was actually typing in my credit card details for the adevrtised newsletter, when I found your site… and came to my senses. Mr. Mauldin’s recommending the other “guru” nearly did the trick.
Best of all, I found the stories & experience shared here realy calming. Thanks 🙂

But then again, my grandchildren may see this differently realizing what then-future “Apple’s” I neglected back in the days…

bosley
Irregular
66
October 27, 2013 6:40 pm

Your grandchildren will love you for who you are, and because you didn’t squander their inheritance on some get rich quick stocks. If you want investment advice and you’re not a Gumshoe irregular, I urge you to join up. You’ll find the most sound unbiased advice anywhere. I was lost in a sea of sharks until I found this site. And no I don’t get paid to say that. Just a grateful newbie.

qwester
Member
2
qwester
October 31, 2013 2:52 pm

Read “Ending Aging” by Aubrey de Grey for the science leading slowly to the Cox “promised land”. The book is ten years old but de Grey has a site somewhere with more recent info. Nothing here is investment related – just science – mostly over my head but more exciting than Cox could ever infer. Maudlin may have touted the wrong guy. Thanks to all Gumshoes for the truth.

guyd
Member
0
guyd
November 1, 2013 8:23 am

Or check out some of Aubrey de Grey’s You Tube speaches, they are a real eye opener. And overall if you want to know about the future overall look at: http://www.singularityweblog.com/

In shot AI/Robotics, nanotechnology and Biotech will be big.

Generalee
Guest
0
Generalee
February 23, 2014 5:00 am
Hmmm, just ran across this page inadvertently after signing up for Patrick Cox’s newsletter via Mauldin Economics in early November. I’ve invested in all 4, Biotime, Nanoviricides, Inovio, and Galectin Therapeutics since the initial recommendations. Biotime is about flat, Nanoviricides after being the victim of a bear raid is down about 20% but was down as much as 40% where I doubled up, Inovio is up about 50% and Galectin Therapeutics is up about 90%, mostly on the back of the very positive news from Intercept Pharma. Maybe I’m being naive or jinxing myself but seems his stock recommendations do… Read more »
wpDiscuz